<DOC>
	<DOCNO>NCT02300363</DOCNO>
	<brief_summary>This study conduct single-center , open-label , 2-period , single-sequence , drug-drug interaction study assess effect multiple-dose LX4211 400 mg ( 2 × 200-mg tablet qd × 7 day ) PK single-dose rosuvastatin ( 1 × 10-mg tablet ) healthy male female subject .</brief_summary>
	<brief_title>DDI Study With Multiple-dose LX4211 Single Dose Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Adult subject ≥18 ≤55 year age Vital sign Screening follow range : systolic blood pressure , 90140 mmHg ; diastolic blood pressure , 5090 mmHg ; heart rate , 45100 bpm Body mass index ( BMI ) ≥18 ≤32 kg/sq Willing able provide write informed consent Presence clinically significant physical , laboratory , ECG finding , opinion Investigator and/or Sponsor , may interfere aspect study conduct interpretation result Use medication supplements/supratherapeutic dos vitamin within 14 day prior first dose administration throughout duration study Receipt investigational agent study drug within 30 day prior Screening Receipt protein antibodybased therapeutic agent within 3 month prior Screening Prior exposure LX4211 Use tobacco , smoke cessation product , product contain nicotine within 3 month prior Screening duration study History serious adverse reaction hypersensitivity inactive component LX4211 rosuvastatin Existence surgical medical condition might interfere absorption , distribution , metabolism , excretion LX4211 rosuvastatin History major surgery within 6 month anticipate surgery prior Day History clinically significant hypoglycemia hyperglycemia History renal disease , significantly abnormal kidney function test Screening History hepatic disease , significantly abnormal liver function test Screening History clinically relevant psychiatric , renal , hepatic , pancreatic , endocrine , cardiovascular , neurological , hematological , GI abnormality History active infection within 14 day prior Day 1 History alcohol substance abuse within 2 year prior Screening Positive hepatitis panel Donation loss &gt; 500 mL blood blood product within 3 month prior Screening Women breastfeed plan become pregnant study , woman positive serum pregnancy test Positive urine glucose Screening Positive urine screen drug abuse cotinine Screening , Day 1 , Day 13 Inability difficulty swallow whole tablet Unable unwilling cooperate Investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>